# Sarilumab for Patients With Moderate COVID-19 Disease

> **NCT04359901** · PHASE2 · COMPLETED · sponsor: **Westyn Branch-Elliman** · enrollment: 50 (actual)

## Conditions studied

- COVID

## Interventions

- **BIOLOGICAL:** SARILUMAB

## Key facts

- **NCT ID:** NCT04359901
- **Lead sponsor:** Westyn Branch-Elliman
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-10
- **Primary completion:** 2021-08-02
- **Final completion:** 2021-08-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359901, "Sarilumab for Patients With Moderate COVID-19 Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04359901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*